Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice